QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

EBS

QT61Emergent BioSolutions Inc.
NYSE·Healthcare·Biotechnology·USA
Latest market price
8.00
-0.14-1.72%
OverviewShort InterestFilings
EBSQT61Emergent BioSolutions Inc.·NYSE
OverviewShort InterestFilings
8.00-1.72%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.28
Insider Own17.37%
Shs Outstand51.60M
Perf Week-4.65%
Market Cap419.99MForward P/E8.79EPS next Y0.91Insider Trans-0.13%Shs Float-Perf Month-0.74%
Enterprise Value833.29MPEG0.41EPS next Q-0.08Inst Own-Short Float-Perf Quarter-0.99%
Income-8567875.00P/S0.62EPS this Y216.07%Inst Trans-Short Ratio-Perf Half Y-34.37%
Sales676.81MP/B0.81EPS next Y180.00%ROA-0.65%Short Interest-Perf YTD-35.28%
Book/sh10.14P/C2.85EPS next 5Y40.43%ROE-1.59%52W High14.06 -43.10%Perf Year28.62%
Cash/sh3.10P/FCF3.10EPS past 3/5Y-ROIC-14.93%52W Low5.62 42.35%Perf 3Y-
Dividend Est.-EV/EBITDA5.39Sales past 3/5Y-12.73% -13.97%Gross Margin44.44%Volatility3.42% 3.41%Perf 5Y-
Dividend TTM-EV/Sales1.23EPS Y/Y TTM127.78%Oper. Margin10.52%ATR (14)0.46Perf 10Y-
Dividend Ex-Date-Quick Ratio2.08Sales Y/Y TTM-35.15%Profit Margin-1.27%RSI (14)45.16Recom2.33
Dividend Gr. 3/5Y-Current Ratio4.29EPS Q/Q-70.42%SMA20-4.46%Beta1.50Target Price12.00
Payout0.00%Debt/Eq1.10Sales Q/Q-29.73%SMA50-4.80%Rel Volume2.89Prev Close8.14
Employees900LT Debt/Eq1.09EarningsAug 05SMA200-17.60%Avg Volume770.58KPrice8.00
IPO DateNov 15, 2006Option/ShortYes / YesEPS/Sales Surpr.184.00% 7.59%Net Debt/EBITDA2.68Volume2,228,269Change-1.72%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-09-26ReiteratedH.C. Wainwright$15 → $12
Mar-07-24UpgradeBenchmarkHold → Buy
Aug-29-23DowngradeBenchmarkBuy → Hold
Apr-10-23UpgradeBenchmarkHold → Buy
Mar-17-23DowngradeJP MorganNeutral → Underweight
Nov-10-22DowngradeBenchmarkBuy → Hold
May-04-22ReiteratedWells FargoEqual Weight$38
Apr-29-22ReiteratedChardan CapitalBuy$65
Nov-08-21DowngradeBenchmarkBuy → Hold
May-05-21DowngradeArgus ResearchBuy → Hold
Latest News
Jun-16-26
Jun-16-2608:50AM
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid OverdoseBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue6777431,044
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A376392668
Gross Profit302351375
Selling, General and Administrative Excl. Other181187299
Research and Development505471
Other Operating Expense-2-1114
Operating Income72110-109
Interest Expense565971
Unusual Expense
———
Non-Operating Income (Expense)12-32-56
Net Income Before Taxes383-143
Income Taxes123048
Consolidated Net Income-953-191
Net Income From Continuing Operations-953-191
Net Income-953-191
EPS (Recurring)-0.170.98-3.60
EPS (Basic, Before Extraordinaries)-0.170.98-3.60
EPS (Diluted)-0.280.93-3.60
EBITDA15624053
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio—13.29—
Price To Sales Ratio0.610.90—
Gross Margin44.6147.2435.92
Operating Margin10.6414.80-10.44
Net Margin-1.337.13-18.30
Shares Outstanding525453
Market Capitalization416667—
Operating Lease Expense
———
Insider Trading Volume
$8.53$8.11$7.70$7.28$6.86● Close Price0.00K97.51K195.03K292.54K390.06KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
DeGolyer Donald WDirectorMay 01 '26Sale8.4015,481129,994129,721May 04 12:00 AM
Dayal Sujata TyagiDirectorMay 01 '26Sale8.4013,761115,610100,563May 04 12:00 AM
Zoon Kathryn CDirectorMay 01 '26Sale8.4017,202144,45379,941May 04 12:00 AM
Katkin KeithDirectorApr 30 '26Sale8.2815,481128,18396,294May 04 12:00 AM
Williams Paul AnthonySVP, Products BusinessApr 01 '26Sale8.444,00033,76062,681Apr 03 12:00 AM
Richard RonaldDirectorDec 05 '25Option Exercise5.0251,496258,510124,165Dec 09 12:00 AM
Richard RonaldDirectorDec 05 '25Sale11.9721,984263,07798,417Dec 09 12:00 AM
DeGolyer Donald WDirectorNov 10 '25Sale10.5417,801187,623119,858Nov 12 12:00 AM
Dayal Sujata TyagiDirectorNov 07 '25Sale10.008,55285,52088,980Nov 10 12:00 AM
Glessner ColeenEVP, Quality & Ethics, and CPLOct 07 '25Sale10.0030,608306,080144,319Oct 16 12:00 AM
Zoon Kathryn CDirectorAug 15 '25Sale8.877,08662,85371,799Aug 18 12:00 AM
DeGolyer Donald WDirectorAug 12 '25Sale8.657,84467,831137,659Aug 13 12:00 AM
Katkin KeithDirectorMay 23 '25Sale6.307,84449,41786,431May 28 12:00 AM
PAPA JOSEPH CPresident and CEOMay 13 '25Buy5.8360,000349,800342,500May 15 12:00 AM
Fowler Neal FranklinDirectorMar 12 '25Sale5.8335,000204,050101,100Mar 12 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR